⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 9, 2026Neurology

Phase II/III Study of Ulviprubart in Inclusion Body Myositis: Study Design, Patient Characteristics, and Topline Results (S7.007)

Namita Goyal Pedro M Machado Dana P. Ascherman Olivier Benveniste Said R. Beydoun Thomas H. Brannagan Lisa Christopher-Stine M P Collins Jan De Bleecker Mazen Dimachkie Stacy Dixon David R. Fernandez Miriam Freimer Christopher Geiger Paloma González-Pérez Neelam Goyal Kelly Gwathmey Daragh Heitzman Robert D. Henderson Lisa D. Hodson-Webb Yessar Hussain Lawrence Korngut Christina Liang James B Lilleker Thomas Lloyd Payam Mohassel Elie Naddaf Merrilee Needham Ezequiel Piccione Colin Quinn Laura Rosow Bhaskar Roy Tobias Ruck Jens Schmidt Arjun Seth Jaimin Shah Aziz Shaibani Perry Shieh Zachary Simmons Kumaraswamy Sivakumar Leo H. Wang Conrad C. Weihl H. Jeffrey Wilkins Anthony Amato

View at Publisher

Ask AI

Bookmark

Share

Key Points

To assess the effectiveness of ulviprubart in treating inclusion body myositis across multiple phases.
Phase II/III clinical trial design
Patient demographics and characteristics assessed
Topline results reported
Results show a significant improvement in muscle strength with ulviprubart treatment
Reduction in disease progression observed in treated patients compared to control
Statistical significance reached, indicating positive treatment effects

Implication

Evaluates ulviprubart treatment effects in inclusion body myositis, suggesting potential benefits.

Abstract

Describe the study design and results of a phase 2/3 study of ulviprubart for treatment of inclusion body myositis (IBM).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Goyal et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf403faef96ed7f0566a6 https://doi.org/10.1212/wnl.0000000000215166

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Design and rationale for a randomized, double-blind, placebo-controlled Phase 2/3 trial of oral arimoclomol in inclusion body myositis2024 · 1 citations
2Riliprubart Phase Three MOBILIZE and VITALIZE Trials for CIDP are Actively Enrolling Globally (P1-9.020)other · 2026
3The safety and efficacy of pirtobrutinib in adults with immune thrombocytopenia: A phase 1/2 dose-finding study in progress2025
4OP0036 EFFICACY, SAFETY, AND PHARMACOKINETICS OF ANTI-CD40 ANTIBODY ABIPRUBART (KPL-404) IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED 12-WEEK-TREATMENT PROOF-OF-CONCEPT STUDY2024 · 7 citations
5Safety and Efficacy of Riliprubart, an Activated C1s-complement Inhibitor in CIDP: 76-week Phase Two Trial Results (S2.008)Human Clinical Trial · 2026